Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study
Clinical Breast Cancer · 2025
DOI: 10.1016/j.clbc.2025.04.016 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Joyce O'Shaughnessy und 16 weiteren Autor:innen. Beteiligte Einrichtung: Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX. Electronic address: Joyce.OShaughnessy@USONCOLOGY.COM. Hauptthemen laut MEDLINE: Trastuzumab, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Roche, F. Hoffmann-La Roche.
Abstract (Originalsprache)
Background
We assessed long-term safety, efficacy, and health-related quality of life during the continuation phase after 3 years' follow-up in PHranceSCa (NCT03674112). Patients and Methods This was a randomized, open-label, international, multicenter, crossover, Phase II study in adjuvant HER2-positive early breast cancer. 159 patients received 3 cycles of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC), then 3 of intravenous pertuzumab and trastuzumab (P + H IV), or vice versa . Post-crossover, patients continued preferred treatment (≤18 cycles total).
Results
Most adverse events, including all cardiac events (n = 2) and anaphylaxis/hypersensitivity (n = 3) were grade 1/2. None were grade 4/5. Grade 1/2 local injection-site reactions occurred in 13 patients (9.4%) receiving PH FDC SC. Other events occurred at comparable rates between arms. The overall event-free rate for invasive disease-free survival was 94.17% (95% confidence interval, 90.47–97.87) at 3 years; overall survival was 98.71% (96.92–100). Meaningful changes from baseline in health-related quality of life included improvements in role and social functioning, and reductions in financial difficulty.
Conclusion
PH FDC SC was well tolerated, with safety consistent with that of P + H IV (except local injection-site reactions) and no grade ≥3 anaphylaxis/hypersensitivity or new safety signals in the continuation period. Immature efficacy data showed high event-free rates, consistent with the known clinical benefit of pertuzumab and trastuzumab (although follow-up was relatively short at 3 years). PHranceSCa adds to the totality of evidence reinforcing the long-term clinical benefit and safety of pertuzumab and trastuzumab. MicroAbstract After 3 years' follow-up in PHranceSCa (NCT03674112), there were no grade 4/5 adverse events in the continuation period; the invasive disease-free survival event-free rate was 94.17% (95% confidence interval, 90.47–97.87); and the overall survival event-free rate was 98.71% (96.92–100). PHranceSCa adds to the totality of evidence reinforcing the long-term clinical benefit and safety of pertuzumab and trastuzumab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX. Electronic address: Joyce.OShaughnessy@USONCOLOGY.COM.
- Breast and Gynecology Oncology Unit, Hospital CUF, Porto, Portugal.
- Department of Medical Oncology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
- Sussex Health Outcomes Research & Education in Cancer (SHORE-C), Brighton & Sussex Medical School, University of Sussex, Falmer, UK.
- Cancer Center, Kuopio University Hospital, Kuopio, Finland.
- Centro de Oncologia, Hospital da Luz Lisboa, Lisbon, Portugal.
Förderung
- Roche
- F. Hoffmann-La Roche
Zitieren
APA
O'Shaughnessy, J., Sousa, S., Cruz, J., Fallowfield, D. L., Auvinen, P., Pulido, C., Cvetanovic, A., Wilks, S., Ribeiro, L., Burotto, M., Boulet, T., Revelant, V., Theron, N., Trask, P., Wahyudi, L., Kirchmayer Machackova, Z., & Stamatovic, L. (2025). Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.04.016
Vancouver
O'Shaughnessy J, Sousa S, Cruz J, Fallowfield DL, Auvinen P, Pulido C, et al. Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.04.016
BibTeX
@article{OShaughnessy2025,
author = {O'Shaughnessy, Joyce and Sousa, Susana and Cruz, Josefina and Fallowfield, Dame Lesley and Auvinen, Päivi and Pulido, Catarina and Cvetanovic, Ana and Wilks, Sharon and Ribeiro, Leonor and Burotto, Mauricio and Boulet, Thomas and Revelant, Valentine and Theron, Nathalie and Trask, Peter and Wahyudi, Laurentia and Kirchmayer Machackova, Zuzana and Stamatovic, Ljiljana},
title = {Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study},
journal = {Clinical Breast Cancer},
year = {2025},
doi = {10.1016/j.clbc.2025.04.016}
}
EUVIMED